DCG-IV

DCG-IV
IUPAC ime
(1R,2R)-3-[(1S)-1-amino-2-hidroksi-2-oksoetil]ciklopropan-1,2-dikarboksilna kiselina
Identifikatori
CAS broj147782-19-2 ДаY
ATC kodnone
PubChemCID 5310979
Hemijski podaci
FormulaC7H9NO6
Molarna masa203,149 g/mol
  • [C@@H]1([C@@H](C1[C@@H](C(=O)O)N)C(=O)O)C(=O)O

DCG-IV je lek koji se koristi u naučnim istraživanjima. On deluje kao agonist za grupu II metabotropnih glutamatnih receptora (mGluR2/3).[1] On ima potentne neuroprotektivne i antikonvulsantne efekte u životinjskim studijama.[2][3][4][5] On isto tako pokazuje antiparkinsonove efekte,[6][7] mada je poznato da usporava formiranje memorija.[8][9]

Reference

[уреди | уреди извор]
  1. ^ Ishida M, Saitoh T, Shimamoto K, Ohfune Y, Shinozaki H (1993). „A novel metabotropic glutamate receptor agonist: marked depression of monosynaptic excitation in the newborn rat isolated spinal cord”. British Journal of Pharmacology. 109 (4): 1169—77. PMC 2175774 Слободан приступ. PMID 8401927. 
  2. ^ Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (1994). „Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death”. European Journal of Pharmacology. 256 (1): 109—12. PMID 7517889. doi:10.1016/0014-2999(94)90624-6. 
  3. ^ Yoshioka H, Sugita M, Kinouchi H (2009). „Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia”. Neuroscience Letters. 461 (3): 266—70. PMID 19549561. doi:10.1016/j.neulet.2009.06.056. 
  4. ^ Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (1998). „Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)”. Brain Research. 805 (1-2): 138—43. PMID 9733953. doi:10.1016/S0006-8993(98)00698-2. 
  5. ^ Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (2006). „Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury”. Journal of Clinical Neuroscience. 13 (10): 1023—7. PMID 17113985. doi:10.1016/j.jocn.2005.11.042. 
  6. ^ Dawson L, Chadha A, Megalou M, Duty S (2000). „The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat”. British Journal of Pharmacology. 129 (3): 541—6. PMC 1571875 Слободан приступ. PMID 10711353. doi:10.1038/sj.bjp.0703105. 
  7. ^ Venero JL, Santiago M, Tomás-Camardiel M, Matarredona ER, Cano J, Machado A (2002). „DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury”. Neuroscience. 113 (4): 857—69. PMID 12182892. doi:10.1016/S0306-4522(02)00232-4. 
  8. ^ Huang LQ, Rowan MJ, Anwyl R (1997). „mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro”. Neuroreport. 8 (3): 687—93. PMID 9106748. doi:10.1097/00001756-199702100-00022. 
  9. ^ Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (2004). „Inhibitory effects of group II mGluR-related drugs on memory performance in mice”. Physiology & Behavior. 80 (5): 747—58. PMID 14984810. doi:10.1016/j.physbeh.2003.12.010. 

Spoljašnje veze

[уреди | уреди извор]